06:59 AM EDT, 09/12/2024 (MT Newswires) -- GSK (GSK) reported "positive headline results" Thursday from a phase II trial of its seasonal influenza vaccine.

The trial included a range of mRNA formulations tested on 500 older and younger adults to find improved immune responses against influenza A and B strains, compared with the current standard of care.

The company said "pre-defined success criteria were met" among all patients.

The vaccine program will soon begin late-stage clinical development, the company said.

Price: 43.62, Change: -0.15, Percent Change: -0.34